Nies Jasper F, Krusche Martin
III. Medizinische Klinik und Poliklinik für Nephrologie, Rheumatologie und Endokrinologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Deutschland.
Z Rheumatol. 2022 Sep;81(7):549-557. doi: 10.1007/s00393-022-01229-x. Epub 2022 Jun 29.
After years of confusion about apparently distinct clinical disease symptoms, the term IgG4-related disease (IgG4-RD) has been coined in 2001, uniting these fibroinflammatory clinical entities with a tendency for tumorous enlargement and tissue fibrosis. Over the past two decades, experimental and clinical studies could make astounding progress in the understanding of this elusive disease. By now, we have a reasonable idea of the pathophysiological mechanisms, which opens up new avenues for therapeutic approaches. It seems like a dense lymphoplasmacytic cell infiltrate, consisting of B‑cells, IgG4 plasma cells, follicular T‑helper cells, CD4 cytotoxic T‑cells and M2 macrophages induces a smoldering inflammatory reaction with a fibrogenic cytokine milieu. This stimulates fibroblasts to secrete extracellular matrix components, leading to the histopathologically characteristic storiform fibrosis and obliterative phlebitis. Macroscopically, this reaction results in diffuse organ swelling and tumorous lesions. The macroscopic and histological differentiation from conditions mimicking IgG4-RD can be challenging. This is especially true for granulomatous diseases, such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The situation is further complicated by the fact that ANCAs can be positive in IgG4-RD and, vice versa IgG4 antibodies can be elevated in numerous differential diagnoses, such as infections, AAV, sarcoidosis, and malignancies. This article provides an overview of the multifaceted clinical condition of IgG4-RD with respect to the pathophysiology, diagnostic steps and treatment. Furthermore, an overview of the differential diagnoses is discussed especially with respect to granulomatous diseases.
在对明显不同的临床疾病症状困惑多年之后,2001年提出了IgG4相关疾病(IgG4-RD)这一术语,将这些具有肿瘤样肿大和组织纤维化倾向的纤维炎性临床实体统一起来。在过去二十年中,实验和临床研究在对这种难以捉摸的疾病的理解上取得了惊人的进展。到目前为止,我们对其病理生理机制有了合理的认识,这为治疗方法开辟了新途径。似乎由B细胞、IgG4浆细胞、滤泡辅助性T细胞、CD4细胞毒性T细胞和M2巨噬细胞组成的致密淋巴细胞浆细胞浸润会引发一种伴有促纤维化细胞因子环境的隐匿性炎症反应。这刺激成纤维细胞分泌细胞外基质成分,导致组织病理学特征性的席纹状纤维化和闭塞性静脉炎。从宏观上看,这种反应导致弥漫性器官肿胀和肿瘤样病变。与模拟IgG4-RD的情况进行宏观和组织学鉴别可能具有挑战性。对于肉芽肿性疾病,如抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)来说尤其如此。由于ANCA在IgG4-RD中可能呈阳性,反之,IgG4抗体在许多鉴别诊断中,如感染、AAV、结节病和恶性肿瘤中可能升高,情况进一步复杂化。本文就IgG4-RD的病理生理学、诊断步骤和治疗方面的多方面临床情况进行概述。此外,还讨论了鉴别诊断的概述,特别是关于肉芽肿性疾病的鉴别诊断。